» Articles » PMID: 9204112

MIB1 Immunopositivity is Associated with Rapid Regrowth of Pituitary Adenomas

Overview
Specialty Neurosurgery
Date 1997 Jan 1
PMID 9204112
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Pituitary adenomas are generally regarded as benign tumours, but they may recur. We identified eight patients with pituitary adenomas that showed rapid regrowth within 2 years of initial surgery. We estimated the percentage of cells in each specimen that showed positive immunostaining for MIB1 (a novel anti-Ki-67) and compared the values to those of 40 adenomas that showed no regrowth. The mean MIB1 index for 40 adenomas that showed no evidence of regrowth was 0.19 +/- 0.06%. This was significantly (p < 0.0001) lower than that for adenomas that showed rapid regrowth (1.27 +/- 0.31%), based on the initial resected specimens. Immediately after detection of rapid regrowth and in adenomas that were resistant to bromocriptine or irradiation, the MIB1 index was always greater than 1.0%. Most patients with rapidly regrowing adenomas were well controlled by radiation therapy. Our results suggest that a MIB1 index greater than 1.0% may be a useful predictor of rapid regrowth of pituitary adenomas and may be useful for planning of therapy.

Citing Articles

K -67/MIB-1 and Recurrence in Pituitary Adenoma.

Tadokoro K, Wolf C, Toth J, Joyce C, Singh M, Germanwala A J Neurol Surg B Skull Base. 2022; 83(Suppl 2):e580-e590.

PMID: 35832982 PMC: 9272325. DOI: 10.1055/s-0041-1735874.


Evaluation of the potential of the Ki67 index to predict tumor evolution in patients with pituitary adenoma.

Petry C, Poli J, de Azevedo Dossin I, Garcia Soares Leaes Rech C, Lima J, Ferreira N Int J Clin Exp Pathol. 2020; 12(1):320-326.

PMID: 31933748 PMC: 6944029.


Predictive modeling for pituitary adenomas: single center experience in 501 consecutive patients.

Pappy 2nd A, Savinkina A, Bicknese C, Neill S, Oyesiku N, Ioachimescu A Pituitary. 2019; 22(5):520-531.

PMID: 31432313 DOI: 10.1007/s11102-019-00982-8.


Clinical Impact of the Current WHO Classification of Pituitary Adenomas.

Saeger W, Honegger J, Theodoropoulou M, Knappe U, Schofl C, Petersenn S Endocr Pathol. 2016; 27(2):104-14.

PMID: 26860936 DOI: 10.1007/s12022-016-9418-7.


Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics.

Balogun J, Monsalves E, Juraschka K, Parvez K, Kucharczyk W, Mete O Endocr Pathol. 2014; 26(1):63-70.

PMID: 25403448 DOI: 10.1007/s12022-014-9347-2.